Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Drugs Fund

- PMLiVE

Keytruda growth helps Merck to offset COVID-19 impact in Q3

Profits beat expectations in the third quarter of 2020

- PMLiVE

Keytruda doubles five-year survival rate in NSCLC

Merck reveals long-term efficacy data for blockbuster immunotherapy

- PMLiVE

Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer

New data from KEYNOTE-590 trial was presented at ESMO 2020 virtual congress

- PMLiVE

Keytruda improves survival in first-line oesophageal cancer

Topline data demonstrates promising efficacy in the first-line setting

AstraZeneca AZ

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

PARP inhibitor now available for rare, life-threatening disease

- PMLiVE

Keytruda hits primary endpoint in confirmatory lymphoma trial

Interim analysis demonstrates improvement in progression-free survival

- PMLiVE

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC

- PMLiVE

FDA sets June decision date for Tecentriq monotherapy in NSCLC

Aims for the first-line setting where Merck's Keytruda dominates

- PMLiVE

Merck’s Ebola vaccine wins approval in four African countries

Follows approvals in US and Europe last year

- PMLiVE

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

Hopes to extend the antibody drug conjugate's use into the earlier setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links